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Abstract
Background: We assessed the degree to which differences in guideline-based medical therapy for
acute myocardial infarction (AMI) contribute to the higher mortality associated with kidney disease.
Methods: In the PREMIER registry, we evaluated patients from 19 US centers surviving AMI. Cox
regression evaluated the association between estimated glomerular filtration rate (GFR) and time
to death over two years, adjusting for demographic and clinical variables. The contribution of
variation in guideline-based medical therapy to differences in mortality was then assessed by
evaluating the incremental change in the hazard ratios after further adjustment for therapy.
Results: Of 2426 patients, 26% had GFR ≥ 90, 44% had GFR = 60- < 90, 22% had GFR = 30- < 60,
and 8% had GFR < 30 ml/min/1.73 m2. Greater degrees of renal dysfunction were associated with
greater 2-year mortality and lower rates of guideline-based therapy among eligible patients. For
patients with severely decreased GFR, adjustment for differences in guideline-based therapy did not
significantly attenuate the relationship with mortality (HR 3.82, 95% CI 2.39–6.11 partially adjusted;
HR = 3.90, 95% CI 2.42–6.28 after adjustment for treatment differences).
Conclusion: Higher mortality associated with reduced GFR after AMI is not accounted for by
differences in treatment factors, underscoring the need for novel therapies specifically targeting the
pathophysiological abnormalities associated with kidney dysfunction to improve survival.
Background
Despite advances in treatment, patients with kidney dis-
ease experience worse outcomes than patients with nor-
mal kidney function following acute myocardial
infarction (AMI) .[1-3] Furthermore, among community
based populations with AMI, as many as half of patients
have moderate to severe kidney disease.[1,4-6] Given the
high prevalence of kidney disease in patients with AMI, it
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is important to understand the mechanisms underlying
the higher rates of adverse outcomes in this population.
The excess risk associated with kidney dysfunction in
patients with AMI may result from biologic factors as well
as differences in treatment with guideline-recommended
therapies. Several pathophysiological mechanisms have
been proposed to explain the progressive increase in risk
with worsening kidney function, including oxidative
stress, inflammation, elevated fibrinogen levels and
derangements in calcium-phosphate homeostasis.[7,8]
Beyond biologic mechanisms, the lower use of therapies
in patients with kidney dysfunction may also contribute
to their higher morbidity and mortality. Although studies
have consistently demonstrated lower use of guideline-
based therapies among patients with kidney dysfunction
and AMI,[1,2,6,9-13] the contribution of this variation in
care to differences in outcomes has been assumed but not
directly assessed.
The objective of this study was to evaluate the contribu-
tion of differential medical treatment to the association
between kidney function and mortality in a community-
based contemporary cohort of post-AMI patients. We
hypothesized that differences in guideline-based medical
therapy would, at least in part, account for the higher mor-
tality associated with kidney dysfunction. Understanding
the extent to which differences in treatment explain differ-
ences in outcomes would help define the importance of
efforts to increase the use of guideline-based therapies
compared with those to develop treatments targeting the
pathophysiological abnormalities conferred by kidney
dysfunction in AMI patients.
Methods
Study Population
Patients were enrolled in the Prospective Registry Evaluat-
ing Myocardial Infarction: Event and Recovery (PRE-
MIER) study, a prospective cohort study of the care and
outcomes of patients after AMI. PREMIER enrolled
patients from 19 US Centers between January 2003 and
June 2004.[14] All patients with a positive troponin test or
elevated CPK-MB fractions were screened for possible
inclusion.
Eligible patients were ≥ 18 years of age, had either an ele-
vated troponin or CPK-MB, had other supporting evi-
dence suggestive of an AMI (e.g. prolonged ischemic
symptoms, electrocardiographic ST changes) and pre-
sented at the enrolling institution or were transferred
within the first 24 hours of symptom onset (to ensure that
primary clinical decision making occurred at the enrolling
site). Patients provided informed consent, approved by
the human subjects review boards at each institution, to
participate.
Of the 2,498 patients enrolled in PREMIER, 2,426 sur-
vived to discharge and had complete data to calculate an
estimated glomerular filtration rate (GFR). (Figure 1)
Variables
The primary predictor variable was kidney function as
quantified by the GFR as calculated using the four variable
Modification of Diet in Renal Disease (MDRD)
forumla.[15] The creatinine used for this calculation was
the measurement closest to the time of hospital discharge.
The GFR was categorized according to recommendations
of the National Kidney Foundation-Kidney Disease Out-
comes Quality Initiative as follows: normal = GFR ≥ 90
mL/min/1.73 m2; mildly impaired = GFR 60- < 90 mL/
min/1.73 m2; moderate dysfunction = GFR 30- < 60 mL/
min/1.73 m2; and severe dysfunction = GFR < 30 mL/
min/1.73 m2.[16]
Patient accounting Figure 1
Patient accounting.
Enrolled in
PREMIER
n=2498
2-year Vital Status 
Known
n=2,386
Total MI Patients
n=3953
1455 unable to or refused consent
GFR known
n=2475
23 cannot calculate GFR
( 9 creatinine missing )
(14 race missing )
Discharged alive
n=2426
17 died in hospital
GFR < 150
n=2443
32 GFR >= 150
40  vital status unknown BMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
Page 3 of 8
(page number not for citation purposes)
A wide range of demographic, cardiac, non-cardiac, and
treatment factors were used for risk adjustment. Records
were abstracted by trained reviewers for clinical comor-
bidities, admission medications, presenting ECG find-
ings, diagnostic study results, final diagnoses, medical
therapies and procedures. Specific medical therapies of
interest were treatment during the first 24 hours with aspi-
rin and beta-blockers and discharge prescription of aspi-
rin, beta-blockers, statins, and angiotensin converting
enzyme inhibitors (ACE inhibitors) or angiotensin recep-
tor blockers (ARBs). Patients were considered eligible for
aspirin, beta blockers and statins if a contraindication or
intolerance to therapy was not documented in the medi-
cal record. Patients considered eligible for ACE inhibitors
or ARBs, were those with at least moderate left ventricular
systolic dysfunction and no contraindication or intoler-
ance to therapy documented in the medical record. Con-
traindications and intolerance to treatments were
collected in a prospective fashion. Contraindications were
not explicitly defined, but rather determined to be present
and documented in the medical record by the treating cli-
nician.
The primary outcome was time to death. Vital status was
confirmed by means of telephone contact and a query of
the National Death Index. Vital status was available for
98% of patients (n = 2,386) at two years. The proportion
missing vital status at two years did not differ by GFR.
Statistical Analysis
Baseline demographic and clinical variables were com-
pared among groups according to categories of GFR using
chi square tests for trends for categorical variables and
ANOVA for continuous variables. The unadjusted associ-
ation between kidney function and treatment rates was
evaluated by comparing proportions of eligible candi-
dates receiving therapy in categories of GFR using chi
square tests. Because of the small numbers of patients
with ESRD, patients receiving hemodialysis were included
in the category of severe kidney dysfunction in the pri-
mary analysis. In secondary analyses of treatment rates,
dialysis patients were considered separately and treatment
rates were compared across all categories of kidney func-
tion.
To evaluate the unadjusted association between categories
of GFR and mortality at two years, Kaplan-Meier survival
curves were constructed and were compared using the log
rank test. Multivariable Cox proportional-hazard regres-
sion, stratified by site, was then used to evaluate the risk-
adjusted association between GFR categories and mortal-
ity. A multivariable model was first constructed including
demographic and clinical variables (age, gender, race,
body mass index (BMI), smoking, cocaine use, alcohol
use, diabetes, hypercholesterolemia, hypertension,
peripheral arterial disease, stroke, chronic lung disease,
arthritis, cancer, prior MI, prior percutaneous coronary
intervention (PCI), prior coronary artery bypass graft
(CABG), heart failure, left ventricular systolic function,
type of MI, maximum troponin, receipt of adjunctive
antiplatelet therapy, receipt of anti-thrombin therapy, pri-
mary reperfusion for ST elevation MI (STEMI), revascular-
ization with PCI, revascularization with CABG). Because
not all patients are eligible for medical therapies (e.g.
some have a documented contraindication or intolerance
to treatment), eligibility may differ across categories of
GFR, and eligibility for therapy may be associated with
differences in mortality, we next adjusted for eligibility for
aspirin, beta blockers, statins, and ACE inhibitor or ARB.
Finally, the use of guideline-based medical therapy with
aspirin (at admission and discharge), beta blockers (at
admission and discharge), statins (at discharge) and ACE
inhibitors or ARBs (at discharge) were added to the
model. The mediation proportion or the incremental con-
tribution of receipt of medications to the observed associ-
ation between categories of GFR and mortality was
evaluated by comparing the hazard ratios for the relation-
ship between kidney function and mortality before and
after adjustment for treatment with medications.
To further assess whether or not the differences in mortal-
ity in categories of GFR were due to differences in treat-
ment, separate models were run restricted to those eligible
for each therapy. Within the cohort restricted to those eli-
gible, the hazard ratios for the relationship between cate-
gories of GFR and mortality before and after adjustment
for treatment with medication were then compared. All
analyses were conducted using SAS software, Version 9.1
(SAS Institute Inc., Cary, NC).
The authors had full access to the data and take responsi-
bility for its integrity.
Results
Of the 2426 patients, 26% (626) had GFR ≥ 90 ml/min/
1.73 m2, 44% (1073) had GFR 60- < 90 ml/min/1.73 m2,
22% (530) had GFR 30- < 60 ml/min/1.73 m2, and 8%
(197) had GFR < 30 ml/min/1.73 m2 or were on hemodi-
alysis (n = 76). Compared with patients with a normal
GFR, patients with lower GFR were older, had lower BMI,
had a higher prevalence of comorbidities, and were more
likely to have had a prior MI, prior CABG and prior PCI
(Table 1). Patients with reduced GFR were more likely to
present with a non-ST elevation MI (NSTEMI) and to have
had higher TIMI risk scores as compared with patients
with normal GFR. Of those who presented with STEMI,
patients with kidney dysfunction were less likely to receive
reperfusion therapy with primary PCI, fibrinolysis or
immediate CABG. Additionally, those with reduced GFR
less frequently underwent coronary angiography or coro-
nary procedures at any time during their hospitalization.BMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
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The proportion of patients eligible for each therapy by
GFR is shown in Table 2. Among those who were eligible
(no documented allergy or contraindication), patients
with reduced GFR were significantly less likely to receive
guideline-based therapies (Table 3). Differences in the
rate of therapy were most marked for aspirin within 24
hours of admission, aspirin at discharge, statins at dis-
charge, and ACE inhibitor or ARB at discharge. The rate of
acute and discharge beta-blocker therapy did not differ
across categories of GFR. Of note, in secondary analyses,
among those who were on dialysis, 89% received aspirin
within 24 hours (p-value for trend across categories of
renal function = 0.003), 80% received aspirin at discharge
(p-value for trend < 0.001), 67% received a statin at dis-
charge (p-value for trend < 0.001), and 64% received an
ACE inhibitor or ARB (p-value for trend < 0.001).
Overall, patients with reduced GFR had higher mortality
rates at two years than patients with normal GFR (Figure
2). A progressive increase in mortality was observed with
decreasing GFR (3% for those with GFR > 90 ml/min/1.73
m2, 4% for GFR 60- < 90 ml/min/m2; 10% for GFR 30- <
60 ml/min/m2 and 28% for GFR < 30 ml/min/m2, p <
0.001).
After adjustment for demographics, comorbidities,
adjunctive thienopyridine therapy, reperfusion and revas-
cularization and eligibility for medical therapies, com-
pared to those with GFR ≥ 90, there was a trend toward
increased 2-year mortality for patients with GFR of 60- <
90 ml/min/m2 (HR = 1.24; 95% CI 0.78–1.97) and GFR
of 30- < 60 ml/min/m2 (HR = 1.56; 95% CI 0.96–2.54)
and significantly higher mortality for those with GFR < 30
Table 1: Baseline characteristics of the population by categories of estimated glomerular filtration rate.
Variable GFR ≥ 90 (n = 626) GFR 60- < 90 (n = 1073) GFR 30- < 60 (n = 530) GFR < 30 (n = 197) p (trend)
Age, mean years (SD) 54 (11) 61 (13) 68 (11) 63 (14) < 0.001
Male (%) 75 71 54 56 < 0.001
Race
White (%) 68 82 78 42 < 0.001
Black (%) 26 14 17 53
Other (%) 6 4 5 5
Non-Cardiac History
BMI, mean kg/m2 (SD) 27.6 (6.1) 29.1 (6.3) 29.3 (6.2) 29.7 (6.7) 0.003
Diabetes (%) 24 22 38 57 < 0.001
Hypercholesterolemia (%) 43 52 52 48 0.002
Hypertension (%) 53 60 77 87 < 0.001
PAD (%) 4 6 11 22 < 0.001
Prior stroke (%) 4 5 10 12 < 0.001
Chronic lung disease (%) 11 12 16 21 < 0.001
Cardiac History
MI (%) 18 20 27 28 < 0.001
CABG (%) 9 10 18 25 < 0.001
PCI (%) 15 17 22 21 0.006
Heart Failure (%) 6 7 19 39 < 0.001
LV Function: normal/mild 
(%)
76 78 68 63 < 0.001
Type of MI (%)
STEMI 49 49 34 11 < 0.001
NSTEMI 51 50 65 88
TIMI STEMI Score (SD) 2.6 (1.8) 3.1 (2.1) 4.7 (2.3) 4.5 (2.5) < 0.001
TIMI NSTEMI Score (SD) 2.8 (1.3) 3.2 (1.3) 3.6 (1.3) 3.3 (1.4) < 0.001
Acute Reperfusion (%) 67 71 49 15 < 0.001
Revascularization (%) 80 78 62 32 < 0.001
Coronary Angiography
All (%) 93 93 82 50 < 0.001
STEMI (%) 96 96 90 60 < 0.001
NESTEMI (%) 89 90 76 47 < 0.001
Laboratory
Hemoglobin (g/dL): mean 
(SD)
14.2 (2.6) 13.9 (1.9) 13.0 (2.1) 11.3 (2.3) < 0.001
Creatinine (mg/dL): mean 
(SD)
0.9 (0.4) 1.1 (0.4) 1.4 (0.5) 5.1 (3.8) < 0.001
Table 1 abbreviations: CABG = coronary artery bypass graft surgery; GFR = glomerular filtration rate (ml/min/1.73 m2); MI = myocardial 
infarction; LV = left ventricular; NSTEMI = non-ST-segment elevation myocardial infarction; PAD = peripheral arterial disease; PCI = percutaneous 
coronary intervention; STEMI = ST segment elevation myocardial infarction; TIMI = Thrombolysis in Myocardial InfarctionBMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
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ml/min/m2 (HR 3.45; 95% CI 2.11–5.64) (Table 4). Fur-
ther adjusting for differences in treatment patterns for
aspirin, beta blockers, statins and ACE inhibitors or ARBs
did not attenuate the association with mortality for
patients with GFR of 60- < 90 ml/min/m2 (HR 1.24; 95%
CI 0.78–1.97), GFR 30- < 60 ml/min/m2 (HR 1.56; 95%
CI 0.96–2.56), or GFR < 30 ml/min/m2 (3.56; 95% CI
2.16–5.87) (Table 4). The results were similar for each
individual therapy when models were restricted to only
those eligible for that therapy.
Discussion
In this community-based population of patients with
AMI, reduced GFR was common, associated with higher
odds of 2-year mortality and yet lower use of guideline-
based medications among eligible patients. However, in
the two years following AMI, the excess mortality associ-
ated with severely reduced GFR persisted after accounting
for variation in clinical and treatment factors. These
results suggest that the underlying pathophysiology of
kidney dysfunction is an important determinant of
adverse outcomes in this population, and that improving
guideline-based care in patients with kidney disease alone
is not likely to close the substantial mortality gap in this
patient population.
Because many clinical trials of AMI therapies exclude
patients with significant kidney disease, the evidence base
for treatment in this population derives primarily from
observational studies, many of which have proposed that
increasing treatment rates in patients with kidney disease
will improve mortality.[6,9,11,12,17] Indeed, multiple
studies have demonstrated under use of guideline-based
therapies in patients with kidney disease.[1,2,6,9-13,18]
While elevating the care for patients with kidney disease is
an important goal, our results suggest that lower treat-
ment rates alone do not account for the excess mortality.
Our findings may differ from those of prior observational
studies for several reasons. First, most studies evaluating
the effectiveness of medical therapies did not account for
eligibility for therapy,[6,12,17] which was explicitly col-
lected in this prospective study. As the factors related to
eligibility may be collinear with treatment, and ineligibil-
ity for treatment may be a marker for adverse outcomes,
the failure to account for differences in eligibility is likely
to result in residual confounding, which may over-esti-
mate the effectiveness of treatments. Only a single study
limited the evaluation of medical therapy to those who
were ideal candidates for individual therapies in patients
with and without end stage kidney disease.[11] However,
this prior study did not adjust for reperfusion or revascu-
larization, procedures that likely confound the relation-
ship between mortality and medical treatment in AMI
patients. PREMIER prospectively collected contraindica-
tions and intolerances to therapy and we adjusted for eli-
gibility for each therapy. Second, intrinsic biases resulting
from selection for angiography make it difficult to inter-
pret the results of an effectiveness study in patients
referred for coronary angiography.[9] PREMIER prospec-
tively enrolled all patients with an AMI, minimizing such
selection biases. Finally, many of the existing studies were
performed over a decade ago, and thus do not reflect con-
temporary treatment for AMI. The current study was con-
ducted in a contemporary cohort of AMI patients. Thus,
more complete control of confounders, fewer selection
biases and the use of contemporary data may account for
Table 2: Proportions of patients eligible for guideline-based therapies by categories of estimated glomerular filtration rate.
Treatment GFR ≥ 90 (n = 626) GFR 60- < 90 (n = 1073) GFR 30- < 60 (n = 530) GFR < 30 (n = 197) p (trend)
Acute aspirin 99.0% 98.5% 97.9% 98.0% 0.114
Acute beta blocker 93.6% 95.6% 93.4% 92.9% 0.531
Discharge aspirin 98.4% 97.6% 96.2% 94.4% 0.001
Discharge beta blocker 94.6% 96.0% 96.2% 95.9% 0.220
Discharge ACE/ARB 22.5% 20.1% 29.1% 27.4% 0.006
Discharge Statin 97.4% 97.3% 95.7% 95.9% 0.073
GFR = glomerular filtration rate (ml/min/1.73 m2)
Table 3: Proportions of eligible patients receiving guideline-based therapies by categories of estimated glomerular filtration rate.
Treatment GFR ≥ 90 (n = 626) GFR 60- < 90 (n = 1073) GFR 30- < 60 (n = 530) GFR < 30 (n = 197) p (trend)
Acute aspirin 98% 96% 97% 93% 0.019
Acute beta blocker 94% 92% 90% 89% 0.166
Discharge aspirin 94% 95% 92% 86% < 0.001
Discharge beta blocker 91% 93% 91% 89% 0.389
Discharge ACE/ARB 84% 92% 81% 56% < 0.001
Discharge statin 83% 84% 76% 69% < 0.001
GFR = glomerular filtration rate (ml/min/1.73 m2)BMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
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the differences in the estimates of the impact of guideline-
based therapies between this and prior studies.
The findings of this study suggest the need for a better
understanding of the efficacy of established therapies for
patients with AMI and kidney dysfunction. Despite the
high and growing prevalence of kidney dysfunction in
patients with AMI, randomized trials of therapies have
generally excluded patients with more than mild kidney
dysfunction, limiting available evidence for the efficacy of
many therapeutic interventions in patients with more
severe kidney dysfunction.[19] Current guideline recom-
mendations for the use of aspirin and beta blockers are
based on older trials which did not include representative
numbers of patients with kidney dysfunction.[20,21] In
fact, in a sample of published randomized controlled tri-
als of therapies for AMI, 66% of trials excluded patients
with kidney disease.[19] More recently, efforts have been
made to evaluate the efficacy of statins and ACE inhibitors
in patients with AMI and kidney dysfunction through sub-
group analyses.[10,22] However, these studies are also
limited by the exclusion criteria applied in the primary
studies. It is crucial that future studies specifically target
those with kidney dysfunction, or at the very least, include
patients with all degrees of kidney dysfunction. Currently,
for many therapies, observational studies provide the best
evidence for treatment of AMI patients with kidney dys-
function.
Our finding that a broad range of clinical and treatment
factors do not account for all of the increased risk of mor-
tality associated with kidney dysfunction suggests that
biologic mechanisms in kidney disease drive the higher
mortality rates in this population. While these mecha-
nisms likely contribute to all-cause mortality, the leading
cause of death in patients with kidney dysfunction is car-
diovascular disease.[7] Accordingly, further research to
elucidate the biologic mechanisms of cardiovascular
abnormalities in patients with kidney disease and develop
novel therapies is needed. Several lines of evidence sug-
gest mechanisms whereby kidney dysfunction may con-
tribute a greater burden of cardiovascular disease. Lipid
abnormalities, increased oxidative stress, inflammation,
hyperhomocysteinemia and impaired nitric oxide bioa-
vailability contribute to atherogenesis and may be more
frequent or severe in kidney disease, resulting in acceler-
ated atherogenesis.[7,8] Increased fibrinogen leads to a
procoaguable state which may increase the likelihood of
thrombotic events in patients with enhanced atheroscle-
rosis.[8] In severe kidney dysfunction anemia, azotemia
and abnormal calcium and phosphate metabolism may
also play a role in cardiovascular pathogenesis.[7,23]
These mechanisms suggest the potential for unique thera-
peutic approaches to improve outcomes in patients with
kidney disease.
Certain factors should be considered in the interpretation
of these results. We did not include follow-up medication
data. Patients may have been started on guideline-based
therapy after discharge from the hospital, or conversely,
Kaplan-Meier survival curve by estimated glomerular filtra- tion rate (GFR, ml/min/1.73 m2) Figure 2
Kaplan-Meier survival curve by estimated glomerular 
filtration rate (GFR, ml/min/1.73 m2).
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p<0.001
Table 4: Hazard ratios (95% confidence intervals) for the relationship between estimated glomerular filtration rate and mortality.
Adjustment: GFR ≥ 90 GFR 60–89 GFR 30–59 GFR < 30
Unadjusted ref 1.44 (0.93–2.25) 3.35 (2.16–5.20) 7.52 (4.85–11.66)
Demographic and clinical variables, + reperfusion/revascularization, 
adjunctive antiplatelet therapy
ref 1.23 (0.77–1.95) 1.51 (0.93–2.46) 3.35 (2.06–5.44)
Demographic and clinical variables, reperfusion/revascularization, adjunctive 
antiplatelet therapy
ref 1.24 (0.78–1.97) 1.56 (0.96–2.54) 3.45 (2.11–5.64)
+ medication eligibility
Demographic and clinical variables, reperfusion/revascularization, adjunctive 
antiplatelet therapy, medication eligibility,
ref 1.24 (0.78–1.97) 1.56 (0.96–2.56) 3.56 (2.16–5.87)
+ receipt of medications
GFR = glomerular filtration rate (ml/min/1.73 m2); ref = referent groupBMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
Page 7 of 8
(page number not for citation purposes)
medications prescribed at the time of discharge may have
been discontinued after discharge. This misclassification
would tend to underestimate the relationship between
therapies and outcomes. However, several studies suggest
that the failure to implement therapy for patients with car-
diovascular disease in the inpatient setting is a strong
marker of the lack of outpatient therapy.[24] Also, we
were not able to focus on the incremental benefit of addi-
tional therapies such as revascularization or other anti-
platelet medications because contraindications to these
therapies were not available. Therefore, we could not dis-
entangle the issue of confounding by eligibility. However,
we were able to assess a number of guideline-recom-
mended therapies for which contraindications were docu-
mented. Furthermore, while some medication utilization
rates were significantly lower in patients with kidney dis-
ease, treatment did not vary significantly for all treat-
ments. Regardless, the substantial residual excess
mortality in patients with severe kidney dysfunction sug-
gests that current medical therapies are not sufficient to
reduce mortality. In addition, contraindications were not
precisely defined. However, contraindications as deemed
present by the treating clinician were prospectively
assessed. Because causes of death were not adjudicated, it
was not possible to identify cardiovascular deaths, which
are those likely to be reduced by guideline-based thera-
pies. However, while chronic kidney disease is associated
with an increased risk of non-cardiovascular mortal-
ity,[25] cardiovascular causes are leading causes of death
in patients with kidney disease and AMI. Among patients
with ESRD with AMI, cardiovascular causes account for
more two thirds of deaths.[26] The estimated GFR during
hospitalization may not reflect a steady state in some
patients with AMI, and measures of albuminuria, an addi-
tional marker of chronic kidney disease, were not availa-
ble. However, the risk for mortality was incrementally
increased with worsening GFR, and persisted after adjust-
ment for other clinical factors, consistent with the existing
literature. Finally, as an observational study, unmeasured
confounding may influence the results. However, we were
able to adjust for a wide range of important measured
demographic and clinical variables.
Conclusion
In the two years following AMI, the excess mortality asso-
ciated with kidney disease was not attributable to a wide
range of clinical and treatment factors, including the
under-use of guideline-based therapy. This study should
not be interpreted as suggesting that guideline-based treat-
ments in patients with AMI and kidney dysfunction are
not effective. Certainly, there is a need for stronger evi-
dence from randomized trials to inform the treatment of
the large number of patients with kidney dysfunction and
cardiovascular disease with existing treatments. However,
these results suggest that the underlying physiology of
kidney disease likely plays an important role in determi-
nation of outcomes. Therefore, novel therapies to treat
patients with kidney dysfunction and cardiovascular dis-
ease are needed to substantially impact the high mortality
observed for the large population of AMI patients with
kidney dysfunction.
Abbreviations
ACE Inhibitors: Angiotensin Converting Enzyme Inhibi-
tor; ARBs: Angiotensin Receptor Blockers; CABG: Coro-
nary Artery Bypass Graft; GFR: glomerular filtration rate;
MI: myocardial infarction; NSTEMI: Non-ST-elevation
myocardial infarction; PCI: Percutaneous Coronary Inter-
vention; PREMIER: Prospective Registry Evaluating Myo-
cardial Infarction: Event and Recovery; STEMI: ST-
elevation myocardial infarction
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PP contributed to the conception and design of the study,
interpretation of data, drafting and critical revision of the
manuscript. AA contributed to the conception and design
of the study and drafting and critical revision of the man-
uscript. PJ contributed to analysis of data, interpretation
of data and drafting and critical revision of the manu-
script. HK contributed to interpretation of data and draft-
ing and critical revision of the manuscript. EK contributed
to interpretation of data and drafting and critical revision
of the manuscript. JS contributed to acquisition of data,
interpretation of data and drafting and critical revision of
the manuscript. JR contributed to the conception and
design of the study and drafting and critical revision of the
manuscript. FM contributed to the conception and design
of the study, interpretation of data and drafting and criti-
cal revision of the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We would like to acknowledge CV Therapeutics for support of the PRE-
MIER registry. CV Therapeutics did not play a role in the design and con-
duct of the study; in the collection, analysis or interpretation of the data; or 
in the preparation, review and approval of the manuscript.
References
1. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS: Renal
insufficiency and mortality from acute coronary syndromes.
American Heart Journal 2004, 147:623-629.
2. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS,
McClellan MB: Association of renal insufficiency with treat-
ment and outcomes after myocardial infarction in elderly
patients.  Ann Intern Med 2002, 137:555-62.
3. Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf
RM, et al.: Prognostic Implications of Abnormalities in Renal
Function in Patients With Acute Coronary Syndromes.  Cir-
culation 2002, 106:974-980.
4. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore
SS, et al.: Serum Urea Nitrogen, Creatinine, and Estimators ofPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2009, 9:29 http://www.biomedcentral.com/1471-2261/9/29
Page 8 of 8
(page number not for citation purposes)
Renal Function: Mortality in Older Patients With Cardiovas-
cular Disease.  Arch Intern Med 2006, 166:1134-1142.
5. McClellan WM, Langston RD, Presley R: Medicare Patients with
Cardiovascular Disease Have a High Prevalence of Chronic
Kidney Disease and a High Rate of Progression to End-Stage
Renal Disease.  J Am Soc Nephrol 2004, 15:1912-1919.
6. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvo-
rak DL, et al.: Acute Myocardial Infarction and Renal Dysfunc-
tion: A High-Risk Combination.  Ann Intern Med 2002,
137:563-570.
7. Dennis VW: Coronary heart disease in patients with chronic
kidney disease.  J Am Soc Nephrol 2005, 16:S103-6.
8. Best PJ, Reddan DN, Berger PB, Szczech LA, McCullough PA, Califf
RM:  Cardiovascular disease and chronic kidney disease:
insights and an update.  American Heart Journal 2004, 148:230-42.
9. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M,
Ghali WA, et al.: The association among renal insufficiency,
pharmacotherapy, and outcomes in 6,427 patients with
heart failure and coronary artery disease.  Journal of the Ameri-
can College of Cardiology 2004, 44:1587-92.
10. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L,
Rouleau JL, et al.: Relation between renal dysfunction and car-
diovascular outcomes after myocardial infarction.  New Eng-
land Journal of Medicine 2004, 351:1285-1295.
11. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and
angiotensin-converting enzyme inhibitor therapy in patients
with end-stage renal disease and an acute myocardial infarc-
tion.  Journal of the American College of Cardiology 2003, 42:201-8.
12. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley
HJ: Benefits of aspirin and beta-blockade after myocardial inf-
arction in patients with chronic kidney disease.  American Heart
Journal 2002, 144:226-32.
13. Han JH, Chandra A, Mulgund J, Roe MT, Peterson ED, Szczech LA, et
al.: Chronic kidney disease in patients with non-ST-segment
elevation acute coronary syndromes.  American Journal of Medi-
cine 2006, 119:248-54.
14. Spertus JA, Peterson E, Rumsfeld JS, Jones PG, Decker C, Krumholz
H: The Prospective Registry Evaluating Myocardial Infarc-
tion: Events and Recovery (PREMIER) – Evaluating the
impact of myocardial infarction on patient outcomes.  Ameri-
can Heart Journal 2006, 151:589-597.
15. Stevens LA, Coresh J, Greene T, Levey AS: Assessing Kidney Func-
tion – Measured and Estimated Glomerular Filtration Rate.
N Engl J Med 2006, 354:2473-2483.
16. K/DOQI clinical practice guidelines for chronic kidney dis-
ease: evaluation, classification, and stratification.  Am J Kidney
Dis 2002, 39:S1-266.
17. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M: Are
we inhibited? Renal insufficiency should not preclude the use
of ACE inhibitors for patients with myocardial infarction and
depressed left ventricular function.  Arch Intern Med 2000,
160:2645-50.
18. Schiele F, Legalery P, Didier K, Meneveau N, Seronde MF, Caulfield F,
et al.: Impact of renal dysfunction on 1-year mortality after
acute myocardial infarction.  American Heart Journal 2006,
151:661-667.
19. Coca SG, Krumholz HM, Garg AX, Parikh CR: Underrepresenta-
tion of Renal Disease in Randomized Controlled Trials of
Cardiovascular Disease.  JAMA 2006, 296:1377-1384.
20. Secondary prevention of vascular disease by prolonged
antiplatelet treatment. Antiplatelet Trialists' Collaboration.
British Medical Journal Clinical Research Ed 1988, 296:320-31.
21. Metoprolol in acute myocardial infarction (MIAMI). A ran-
domised placebo-controlled international trial. The MIAMI
Trial Research Group.  Eur Heart J 1985, 6:199-226.
22. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G, Cholesterol Recur-
rent Events (CARE) Trial Investigators: Pravastatin for secondary
prevention of cardiovascular events in persons with mild
chronic renal insufficiency.  Ann Intern Med 2003, 138:98-104.
23. Schrier RW: Role of diminished renal function in cardiovascu-
lar mortality: marker or pathogenetic factor?  Journal of the
American College of Cardiology 2006, 47:1-8.
24. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR:
Outpatient utilization of angiotensin-converting enzyme
inhibitors among heart failure patients after hospital dis-
charge.  Journal of the American College of Cardiology 2004,
43:2036-2043.
25. Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, et al.:
Kidney function as a predictor of noncardiovascular mortal-
ity.  J Am Soc Nephrol 2005, 16:3728-3735.
26. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after
acute myocardial infarction among patients on long-term
dialysis.  N Engl J Med 1998, 339:799-805.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/9/29/prepub